Psychotropic prescribing in long-term care facilities: Impact of medication reviews and educational interventions

American Journal of Geriatric Psychiatry

Volumn 16, Issue 8, 2008, Pages 621-632

  Nishtala, Prasad S ^a   McLachlan, Andrew J ^a,b   Bell, J Simon ^a,c   Chen, Timothy F ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Educational interventions; Long term care facilities; Medication review; Psychotropic drugs

Indexed keywords

DIAZEPAM; PSYCHOTROPIC AGENT;

AGGRESSION; AGITATION; ARTICLE; CINAHL; COCHRANE LIBRARY; COGNITION; CONFIDENCE INTERVAL; DEPRESSION; DRUG INFORMATION; DRUG USE; EMBASE; GERIATRIC PATIENT; HUMAN; HYPNOSIS; INTERVENTION STUDY; LONG TERM CARE; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PHARMACIST; PRESCRIPTION; PREVALENCE; PSYCINFO; RESIDENTIAL HOME; STRUCTURED INTERVIEW; AGED; CONTINUING EDUCATION; DRUG UTILIZATION; HOME FOR THE AGED; META ANALYSIS; NURSING HOME; PEER REVIEW; REVIEW;

AGED; DRUG UTILIZATION; EDUCATION, CONTINUING; HOMES FOR THE AGED; HUMANS; LONG-TERM CARE; NURSING HOMES; PEER REVIEW, HEALTH CARE; PSYCHOTROPIC DRUGS;

EID: 54549085523     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e31817c6abe     Document Type: Article

References (76)

1. Fenton J, Raskin A, Gruber-Baldini AL, et al: Some predictors of psychiatric consultation in nursing home residents. Am J Geriatr Psychiatry 2004; 12:297-304
2. Borson S, Loebel JP, Kitchell M, et al: Psychiatric assessments of nursing home residents under OBRA-87: should PASARR be reformed? Pre-admission screening and annual review. J Am Geriatr Soc 1997; 45:1173-1181
3. Matthews FE, Dening T: Prevalence of dementia in institutional care. Lancet 2002; 360:225-226
4. Bartels SJ, Horn SD, Smout RJ, et al: Agitation and depression in frail nursing home elderly patients with dementia: treatment characteristics and service use. Am J Geriatr Psychiatry 2003; 11:231-238
5. Beardsley RS, Larson DB, Burns BJ, et al: Prescribing of psychotropics in elderly nursing home patients. J Am Geriatr Soc 1989; 37:327-330
6. Hosia-Randell H, Pitkala K: Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging 2005; 22:793-800
7. Kay DW, Holding TA, Jones B, et al: Psychiatric morbidity in Hobart's dependent aged. Aust N Z J Psychiatry 1987; 21:463-475
8. Draper B, Brodaty H, Low LF, et al: Use of psychotropics in Sydney nursing homes: associations with depression, psychosis, and behavioral disturbances. Int Psychogeriatr 2001; 13:107-120
9. Snowdon J, Vaughan R, Miller R, et al: Psychotropic drug use in Sydney nursing homes. Med J Aust 1995; 163:70-72
10. Yip YB, Cumming RG: The association between medications and falls in Australian nursing-home residents. Med J Aust 1994; 160:14-18
11. Cumming RG, Le Couteur DG: Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17:825-837
12. Hubbard R, Farrington P, Smith C, et al: Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003; 158:77-84
13. Ray WA, Griffin MR, Schaffner W, et al: Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316:363-369
14. Thapa PB, Gideon P, Fought RL, et al: Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995; 142:202-211
15. Herings RM, Stricker BH, de Boer A, et al: Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155:1801-1807
16. Paterniti S, Dufouil C, Alperovitch A: Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002;22:285-293
17. Ried LD, Johnson RE, Gettman DA: Benzodiazepine exposure and functional status in older people. J Am Geriatr Soc 1998; 46:71-76
18. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
19. Gareri P, De Fazio P, De Fazio S, et al: Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006; 23:937-956
20. Raivio MM, Laurila JV, Strandberg TE, et al: Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 2007; 15:416-424
21. Hollis J, Grayson D, Forrester L, et al: Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007; 15:932-941
22. Ness J, Hoth A, Barnett MJ, et al: Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006; 4:42-51
23. Ancelin ML, Artero S, Portet F, et al: Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332:455-459
24. Kara AB, Juan CS, Lei Y, et al: Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006; 14:980
25. Teri L, Reifler BV, Veith RC, et al: Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 1991; 46:P372-P377
26. Hilmer SN, Mager DE, Simonsick EM, et al: A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167:781-787
27. Field TS, Gurwitz JH, Avorn J, et al: Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161:1629-1634
28. Hilmer SN, McLachlan AJ, Le Couteur DG: Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007; 21:217-230
29. Routledge PA, O'Mahony MS, Woodhouse KW: Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004; 57:121-126
30. Sutcliffe C, Burns A, Challis D, et al: Depressed mood, cognitive impairment, and survival in older people admitted to care homes in England. Am J Geriatr Psychiatry 2007; 15:708-715
31. Bell S, McLachlan AJ, Aslani P, et al: Community pharmacy services to optimize the use of medications for mental illness: a systematic review. Aust New Zealand Health Policy 2005; 2:29
32. Furniss L, Burns A, Craig SK, et al: Effects of a pharmacist's medication review in nursing homes. Randomised controlled trial. Br J Psychiatry 2000; 176:563-567
33. Schmidt I, Claesson CB, Westerholm B, et al: The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. J Am Geriatr Soc 1998; 46:77-82
34. Schmidt IK, Fastbom J: Quality of drug use in Swedish nursing homes. A follow-up study. Clin Drug Investig 2000; 20:433-446
35. Roberts MS, Stokes JA, King MA, et al: Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol 2001; 51:257-265
36. Avorn J, Soumerai SB, Everitt DE, et al: A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes [see comment]. N Engl J Med 1992; 327:168-173
37. Crotty M, Whitehead C, Rowett D, et al: An outreach intervention to implement evidence based practice in residential care: a randomized controlled trial [ISRCTN67855475]. BMC Health Serv Res 2004; 4:6
38. Fossey J, Ballard C, Juszczak E, et al: Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 2006; 332:756-761
39. Ray WA, Blazer DG II, Schaffner W, et al: Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. Am J Public Health 1987; 77:1448-1450
40. Ray WA, Taylor JA, Meador KG, et al: Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education. Arch Intern Med 1993; 153:713-721
41. Meador KG, Taylor JA, Thapa PB, et al: Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education. J Am Geriatr Soc 1997; 45:207-210
42. Eide E, Schjott J: Assessing the effects of an intervention by a pharmacist on prescribing and administration of hypnotics in nursing homes. Pharm World Sci 2001; 23:227-231
43. Hughes CM, Lapane KL: Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been? Drugs Aging 2005; 22:339-351
44. Roughead EE, Semple SJ, Gilbert AL: Quality use of medicines in aged-care facilities in Australia. Drugs Aging 2003; 20:643-653
45. O'Brien MA, Oxman AD, Davis DA, et al: Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2000; CD000409
46. WHO Collaborating Centre for Drug Statistics Methodology. Available at: www.whocc.no/atcddd/. Accessed January 21, 2008
47. Sutton AJ, Jones DR, Abrams KR, et al: Systematic reviews and meta-analysis: a structured review of the methodological literature. J Health Serv Res Policy 1999; 4:49-55
48. DerSimonian R, Kacker R: Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28:105-114
49. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560
50. Cole MM, Jacobs M, Solver B: Unnecessary medications: cost savings resulting from interdisciplinary assessments of medications regimens. Consult Pharm 1996; 11:933
51. Cooper JW Jr: Consultant pharmacist drug therapy recommendations from monthly drug regimen reviews in a geriatric nursing facility: a two-year study and cost analysis. J Nutr Health Aging 1997; 1:181-184
52. Miller SW: Impact of pharmacist-conducted drug-regimen review on drug use in an intermediate-care facility. Consult Pharm 1991; 5:317-322
53. Ruggiero RJ, Cohen KR, Lauletta J, et al: Further exploration of the economic impact of pharmacist intervention at the point of polypharmacy prescribing: follow up study. Pharm Therap 1997; 22:555-556, 558, 563-566, 572, 578
54. Trygstad TK, Christensen D, Garmise J, et al: Pharmacist response to alerts generated from Medicaid pharmacy claims in a long-term care setting: results from the North Carolina polypharmacy initiative. J Manag Care Pharm 2005; 11:575-583
55. Thornley SM, Carmichael JM, Bryg RJ: Effect of clinical pharmacy input on physician prescribing habits in the nursing home care unit. Hosp Pharm 27:616-617
56. Hirshfield JS: Positive patient outcomes from interdisciplinary assessments of psychoactive drug use. Consult Pharm 1993; 8:532-534
57. Bellingan M, Wiseman IC: Pharmacist intervention in an elderly care facility. Int J Pharm Pract 1996; 4:25-29
58. Lapane KL, Hughes CM: Adherence to the components of the Fleetwood model: self-reported process measures in the Fleetwood Phase III study. Consult Pharm 2006; 21:981-987
59. Christensen D, Trygstad T, Sullivan R, et al: A pharmacy management intervention for optimizing drug therapy for nursing home patients. Am J Geriatr Pharmacother 2004; 2:248-256
60. Laucka PV, Hoffman NB: Decreasing medication use in a nursing-home patient-care unit. Am J Hosp Pharm 1992; 49:96-99
61. Neel AB, Pittman JC, Marasco RA, et al: Psychoactive drug use in Georgia nursing homes: effects of aggressive intervention. Consult Pharm 1993; 8:245-248
62. Witte KW, Leeds NH, Pathak DS, et al: Drug regimen review in skilled nursing facilities by consulting clinical pharmacists. Am J Hosp Pharm 1980; 37:820-824
63. Khunti K, Kinsella B: Effect of systematic review of medication by general practitioner on drug consumption among nursing-home residents. Age Ageing 2000; 29:451-453
64. Lau W-M, Chan K, Yung T-H, et al: Outreach pharmacy service in old age homes: a Hong Kong experience. J Chin Med Assoc 2003; 66:346-354
65. Zermansky AG, Alldred DP, Petty DR, et al: Clinical medication review by a pharmacist of elderly people living in care homes-randomised controlled trial. Age Ageing 2006; 35:586-591
66. Rumble R: Cost Effectiveness of Consultant Pharmacist Services Provided to Hostel Residents: Final Report to the Commonwealth. Hobart Australia, University of Tasmania, 1996
67. Hughes CM, Lapane K, Watson MC, et al: Does organizational culture influence prescribing in care homes for older people? A new direction for research. Drugs Aging 2007; 24:81-93
68. Svarstad BL, Mount JK: Chronic benzodiazepine use in nursing homes: effects of federal guidelines, resident mix, and nurse staffing. J Am Geriatr Soc 2001; 49:1673-1678
69. Shorr RI, Fought RL, Ray WA: Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA 1994; 271:358-362
70. Garrard J, Chen V, Dowd B: The impact of the 1987 federal regulations on the use of psychotropic drugs in Minnesota nursing homes. Am J Public Health 1995; 85:771-776
71. Finkers F, Maring JG, Boersma F, et al: A study of medication reviews to identify drug-related problems of polypharmacy patients in the Dutch nursing home setting. J Clin Pharm Ther 2007; 32:469-476
72. Ruths S, Straand J, Nygaard HA: Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BED-NURS) study. Qual Saf Health Care 2003; 12:176-180
73. Hawe P, Shiell A, Riley T: Complex interventions: how "out of control" can a randomised controlled trial be? BMJ 2004; 328:1561-1563
74. Lonergan E, Britton AM, Luxenberg J, et al: Antipsychotics for delirium. Cochrane Database Syst Rev 2007; CD005594
75. Fahey T, Schroeder K, Ebrahim S: Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2006; CD005182
76. Margallo-Lana M, Swann A, O'Brien J, et al: Prevalence and pharmacological management of behavioral and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16:39-44